Cantor analyst Bryan Brokmeier reiterated a Buy rating on shares of Cerus Corporation (NASDAQ:CERS), with a $9.00 price target, after the FDA announced that it is requesting that …
In a research report sent to investors Thursday, Cantor analyst Bryan Brokmeier assumed coverage on shares of Cerus Corporation (NASDAQ:CERS), with a Buy rating and price …
Analyst Catherine Ramsey of Robert W. Baird is bullish on EXACT Sciences Corporation (NASDAQ:EXAS) and Cerus Corporation (NASDAQ:CERS) following positive developments surrounding their products.
Pipeline updates from biotech companies Cerus Corporation (NASDAQ:CERS) and Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) cause analysts to reiterate Buy ratings on both, highlighting various …
Analyst Thomas Yip of FBR & Co is Bullish on biotech companies Peregrine Pharmaceuticals (NASDAQ:PPHM) and Cerus Corporation (NASDAQ:CERS). The analyst remains positive …
The volatile biotech sector did not fail to live up to its reputation this week. Analysts weigh in on Cerus Corporation (NASDAQ:CERS) as …
Cerus Corporation (NASDAQ:CERS) announced that Unyts has signed a three-year purchase agreement for the INTERCEPT Blood System for platelets and plasma. Unyts provides blood …
Cerus Corporation (NASDAQ:CERS) announced that Bonfils Blood Center has signed a three-year purchase agreement for the INTERCEPT Blood System for platelets and plasma. Bonfils …
Cerus Corporation (NASDAQ:CERS) announced financial results for the first quarter ended March 31, 2015. Recent company highlights include: Signed INTERCEPT platelet and plasma supply …
